Literature DB >> 8627839

Outcomes of initial surveillance of invasive squamous cell carcinoma of the penis and negative nodes.

D Theodorescu1, P Russo, Z F Zhang, C Morash, W R Fair.   

Abstract

PURPOSE: We determined factors predictive of inguinal nodal relapse in patients with stages T1 to 3NOMO squamous cell penile cancer treated initially with surveillance of inguinal nodes.
MATERIALS AND METHODS: Between 1980 and 1994, in 42 patients with stages T1 to 3NOMO squamous cell penile cancer of 60 with invasive disease seen at our center the inguinal nodes were surveyed after definitive treatment of the primary tumor. Clinical inguinal nodal recurrences were treated with inguinal lymphadenectomy.
RESULTS: A total of 26 patients (62%) had inguinal nodal recurrences during followup, with 50% occurring within 1.4 years and 75% within 2.8 years of resection of the primary tumor. The only factor predicting nodal relapse was grade of the primary tumor at initial treatment. Patients with grade 1 tumors had a 45% long-term actuarial relapse-free survival rate. All other groups had a 100% actuarial nodal relapse rate. Of the patients 10% had metastatic disease without nodal recurrence.
CONCLUSIONS: Invasive penile cancer may be associated with inguinal lymph node and hematogenous metastasis. A strong case for prophylactic bilateral inguinal lymphadenectomy can be made in patients with primary tumors other than grade 1, since surveillance of these patients will not spare them eventual lymphadenectomy and may potentially compromise survival by delaying surgery. Patients with grade 1 tumors may be offered either careful surveillance or prophylactic bilateral inguinal lymphadenectomy depending on the clinical circumstances and patient preference.

Entities:  

Mesh:

Year:  1996        PMID: 8627839

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

1.  Penile cancer: a case for guidelines.

Authors:  N P Munro; P J Thomas; G P Deutsch; N J Hodson
Journal:  Ann R Coll Surg Engl       Date:  2001-05       Impact factor: 1.891

2.  Hidden penile squamous cell carcinoma: A case report.

Authors:  Sam Neufeld; Tadeusz Kroczak; Darrel Drachenberg
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

Review 3.  Penile preserving and reconstructive surgery in the management of penile cancer.

Authors:  Arthur L Burnett
Journal:  Nat Rev Urol       Date:  2016-03-22       Impact factor: 14.432

4.  Inguinal Lymph Nodes in Carcinoma Penis-Observation or Surgery?

Authors:  Syed Althaf; Rajkumar P Narayanakar; Dinesh M Gangaiah; Kapil Dev; Vishnu P Kurpad; Jaiprakash Gurawalia
Journal:  J Clin Diagn Res       Date:  2016-01-01

5.  What next? Managing lymph nodes in men with penile cancer.

Authors:  Michael Leveridge; D Robert Siemens; Christopher Morash
Journal:  Can Urol Assoc J       Date:  2008-10       Impact factor: 1.862

Review 6.  [Penile cancer--aftercare with results. How much is necessary?].

Authors:  R Paul; H van Randenborgh; S Schöler; F May; R Hartung
Journal:  Urologe A       Date:  2005-09       Impact factor: 0.639

Review 7.  Current trends in the management of carcinoma penis--a review.

Authors:  Iqbal Singh; A Khaitan
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

8.  Contemporary management of penile cancer including surgery and adjuvant radiotherapy: an experience in Taiwan.

Authors:  Miao-Fen Chen; Wen-Cheng Chen; Chun-Te Wu; Cheng-Keng Chuang; Kwai-Fong Ng; Joseph Tung-Chieh Chang
Journal:  World J Urol       Date:  2003-12-05       Impact factor: 4.226

9.  Carcinoma penis: How late can inguinal nodal metastases occur?

Authors:  Anil Kamath; T B Yuvaraja; H B Tongaonkar; S Kane
Journal:  Indian J Urol       Date:  2007-07

10.  Predictive pathological factors of lymph nodes involvement in the squamous cell carcinoma of the penis.

Authors:  Vincenzo Ficarra; Guido Martignoni; Nicola Maffei; Maria Angela Cerruto; Giacomo Novara; Stefano Cavalleri; Walter Artibani
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.